Loading…
Warby Parker Inc. sells eyewear products through its retail and e-commerce platform in the United States and Canada. The company offers eyeglasses and sunglasses; and single-vision, progressive, light-responsive, polarized, blue-light-filtering, tinted, non-prescription, and contact lenses. It also provides accessories, such as cases, pouches, lenses kit with anti-fog spray, travel cases, lenses cloth, anti-fog lens spray, and sun clip-ons through its stores, website, and mobile apps. In addition, the company offers eye exams and vision tests, as well as optical services. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $872M | $45M | $2M | $44M | 0.4% | 13.0% | -108.0% |
| 2024 | $771M | $16M | $-20M | $35M | -6.0% | 15.2% | -67.7% |
| 2023 | $670M | $-33M | $-63M | $7M | -20.9% | 12.0% | -42.8% |
| 2022 | $598M | $-79M | $-110M | $-50M | -38.5% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 598.11 | 669.76 | 771.32 | 871.90 |
| Operating Revenue | - | 598.11 | 669.76 | 771.32 | 871.90 |
| Cost Of Revenue | - | 257.05 | 304.54 | 344.48 | 401.33 |
| Gross Profit | - | 341.06 | 365.22 | 426.83 | 470.58 |
| Operating Expense | - | 452.26 | 437.22 | 456.95 | 475.92 |
| Selling General And Administration | - | 452.26 | 437.22 | 456.95 | 475.92 |
| Total Expenses | - | 709.32 | 741.76 | 801.43 | 877.24 |
| Operating Income | - | -111.20 | -72 | -30.11 | -5.34 |
| Total Operating Income As Reported | - | -111.20 | -72 | -30.11 | -5.34 |
| EBITDA | - | -79.34 | -33.44 | 15.75 | 44.94 |
| Normalized EBITDA | - | -79.34 | -33.44 | 15.75 | 44.94 |
| EBIT | - | -111.20 | -72 | -30.11 | -5.34 |
| Net Interest Income | - | 1.31 | 9.23 | 10.60 | 8.38 |
| Net Non Operating Interest Income Expense | - | 1.31 | 9.23 | 10.60 | 8.38 |
| Pretax Income | - | -109.90 | -62.76 | -19.52 | 3.04 |
| Tax Provision | - | 0.50 | 0.43 | 0.88 | 1.40 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -110.39 | -63.20 | -20.39 | 1.64 |
| Net Income From Continuing And Discontinued Operation | - | -110.39 | -63.20 | -20.39 | 1.64 |
| Net Income From Continuing Operation Net Minority Interest | - | -110.39 | -63.20 | -20.39 | 1.64 |
| Net Income | - | -110.39 | -63.20 | -20.39 | 1.64 |
| Net Income Common Stockholders | - | -110.39 | -63.20 | -20.39 | 1.64 |
| Net Income Including Noncontrolling Interests | - | -110.39 | -63.20 | -20.39 | 1.64 |
| Normalized Income | - | -110.39 | -63.20 | -20.39 | 1.64 |
| Diluted NI Availto Com Stockholders | - | -110.39 | -63.20 | -20.39 | 1.64 |
| Basic Average Shares | 71.25 | 114.94 | 117.39 | 120.38 | - |
| Diluted Average Shares | 71.25 | 114.94 | 117.39 | 120.38 | - |
| Reconciled Depreciation | - | 31.86 | 38.55 | 45.86 | 50.28 |
| Reconciled Cost Of Revenue | - | 257.05 | 304.54 | 344.48 | 401.33 |
| Preferred Stock Dividends | 13.14 | - | - | - | - |
| Total Other Finance Cost | - | -1.31 | -9.23 | -10.60 | -8.38 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Warby Parker Inc.this co. | WRBY | $3.0B | 1803.71↑ premium | 8.05 | 0.4% | 64.67 |
| Option Care Health, Inc. | OPCH | $3.2B | 15.18 | 2.38 | 15.6% | 10.27 |
| Alignment Healthcare, Inc. | ALHC | $3.1B | - | 17.38 | -0.4% | 62.69 |
| Dyne Therapeutics, Inc. | DYN | $3.0B | -6.82 | 3.13 | -45.9% | -5.30 |
| LifeStance Health Group, Inc. | LFST | $2.9B |
| - |
| - |
| - |
| - |
| - |
| 301.90 |
| 1.92 |
| 0.6% |
| 39.90 |
| Adaptive Biotechnologies Corporation | ADPT | $2.9B | - | 13.23 | -27.2% | - |
| GRAIL, Inc. | GRAL | $2.9B | -6.99 | 1.11 | -15.8% | -7.04 |
| Brookdale Senior Living Inc. | BKD | $2.8B | -10.81 | -63.45 | 587.0% | 23.48 |
| Soleno Therapeutics, Inc. | SLNO | $2.8B | 132.26 | 6.14 | 4.6% | 96.72 |
| Peer Median | - | 4.18 | 2.75 | 0.1% | 23.48 | |